Xtant Medical Holdings, Inc. reported second-quarter 2026 total revenue of $23 million, down from $35.4 million a year earlier, and reduced its full-year revenue guidance to a range of $99 million to $103 million from the prior $101 million to $105 million. On a pro forma basis excluding divested assets and terminated license revenue, revenue was $23 million compared with $24.8 million in the second quarter of 2025, with the decline driven by headwinds in the amniotic product line tied to the advanced wound care market. HEMOBLAST Bellows contributed $1.5 million in revenue, recognized primarily on a net basis as customers remained on Dilon Technologies agreements, and the company missed an estimated $600,000 to $700,000 in additional reported revenue because transactions were not yet processed through its own system. Gross margin fell to 57.9% from 68.6%, operating expenses rose to $22.5 million including a $5 million exclusivity fee paid to Dilon, and the net loss was $9.4 million, or $0.07 per share, compared with net income of $3.6 million in the prior-year quarter. The company integrated 17 sales professionals and two regional managers from Dilon, expanding its commercial footprint to over 25 representatives, and expects the transition to gross revenue recognition for HEMOBLAST and cross-selling of biologics to drive accelerating growth in the second half of 2026.
Xtant Medical Holdings IncQ2 revenue fell and full-year guidance was cut to $99–$103M from $101–$105M, with net loss of $9.4M.
Dilon is mentioned as the source of an exclusivity fee and agreements, but its own financial impact is not detailed.
